| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1186 | |
| Phytochemical name or plant extracts | Bezielle (BZL101) | |
| PMID | 20574166 | |
| Literature evidence | In late stage hormone insensitive breast (MDA-MB-231) and prostate (PC3) cancer cells, BZL101 induced an S phase arrest with corresponding ablations in Cyclin A2 and CDK2 expression. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Scutellaria barbata | |
| Geographical availability | Assam, Bangladesh, China South-Central, China Southeast, East Himalaya, Japan, Korea, Laos, Myanmar, Nepal, Taiwan, Thailand, Vietnam, West Himalaya | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Prostate cancer | |
| Target gene or protein | Cyclin A2, Cyclin D1, CDK2, CDK4, ERα | |
| Gene or Protein evidence | In late stage hormone insensitive breast (MDA-MB-231) and prostate (PC3) cancer cells, BZL101 induced an S phase arrest with corresponding ablations in Cyclin A2 and CDK2 expression. In early stage estrogen sensitive MCF7 cells, BZL101 induced a G₁ cell cycle arrest and ablated expression of key G₁ cell cycle regulators Cyclin D1, CDK2 and CDK4, as well as growth factor stimulatory pathways and estrogen receptor-α expression. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Our results demonstrate that BZL101 exerts phenotype specific anti-proliferative gene expression responses in human breast and prostate cancer cells, which will be valuable in the potential development of BZL-based therapeutic strategies for human reproductive cancers. | |
| Cell line/ mice model | MCF-7, MDA-MB-231, LNCaP, PC3 | |
| Additional information | In this Phase 2 trial, 40 participants with hormone receptor positive tumors and 40 with hormone receptor negative tumors will be enrolled and treated with BZL101 20 grams/day (10 grams BID). Hormone receptor positive will be defined as estrogen receptor (ER)+ and progesterone receptor (PR)+, ER+ and PR-, or ER- and PR+. Hormone receptor negative will be defined as ER- and PR-..,BZL101 treatment leads to the inhibition of glycolysis selectively in tumor cells, evident from the decrease in the enzymatic activities within the glycolytic pathway and the inhibition of lactate production. | |
| PubChem ID | NA | |
| Additional PMIDs | 20574166 18305410 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:458159-1 | |
| Safety | NA |